| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.
What Happened: Effective prior to the opening of trading on June 3, Sarepta Therapeutics will join the S&P MidCap 400, replacing Shockwave Medical (NASDAQ:SWAV).
Johnson & Johnson (NYSE:JNJ) is expected to acquire Shockwave Medical in a deal that is currently pending final closing conditions. Johnson and Johnson is an S&P 500 constituent.
Related Link: Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Sarepta Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
SRPT Price Action: Sarepta Therapeutics shares were up 6.67% at $123.99 at the time of publication, according to data from Benzinga Pro.
Image: Courtesy of Sarepta Therapeutics, Inc.
